Suppression of high-fat diet-induced obesity-associated liver mitochondrial dysfunction by docosahexaenoic acid and hydroxytyrosol co-administration

dc.creatorOrtiz, Macarena
dc.creatorSoto-Alarcón, Sandra A.
dc.creatorOrellana, Paula
dc.creatorEspinosa, Alejandra
dc.creatorCampos, Cristian
dc.creatorLópez-Arana, Sandra
dc.creatorRincón-Cervera, Miguel Ángel
dc.creatorIllesca, Paola
dc.creatorValenzuela, Rodrigo
dc.creatorVidela, Luis A.
dc.date2023-04-18T14:53:58Z
dc.date2023-04-18T14:53:58Z
dc.date2020
dc.date.accessioned2024-05-02T20:31:01Z
dc.date.available2024-05-02T20:31:01Z
dc.identifierhttp://repositorio.ucm.cl/handle/ucm/4681
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/9274920
dc.descriptionObjective: Obesity-induced by high-fat diet (HFD) is associated with liver steatosis, oxidative stress and mitochondrial dysfunction, which can be eluded by the co-administration of the lipid metabolism modulator docosahexaenoic acid (DHA) and the antioxidant hydroxytyrosol (HT). Methods: C57BL/6J mice fed a HFD were orally administered either with vehicle, DHA, HT or DHA+HT for 12 weeks. We measured parameters related to insulin resistance, serum lipid levels, liver fatty acid (FA) content and steatosis score, concomitantly with those associated with mitochondrial energy functions modulated by the transcriptional coactivator PGC-1a. Results: HFD induced insulin resistance, liver steatosis with n−3 FA depletion, and loss of mitochondrial respiratory functions with diminished NAD+/NADH ratio and ATP levels compared with CD, with the parallel decrease in the expression of the components of the PGC-1α cascade, namely, PPAR-α, FGF21 and AMPK, effects that were not observed in mice subjected to DHA and HT co-administration. Conclusions: Data presented indicate that the combination of DHA and HT prevents the development of liver steatosis and the associated mitochondrial dysfunction induced by HFD, thus strengthening the significance of this protocol as a therapeutic strategy avoiding disease evolution into more irreversible forms characterised by the absence of adequate pharmacological therapy in human obesity.
dc.languageen
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.sourceDigestive and Liver Disease, 52(8), 895-904
dc.subjectHigh-fat diet
dc.subjectLiver steatosis
dc.subjectMitochondrial dysfunction
dc.subjectDocosahexaenoic acid
dc.subjectHydroxytyrosol
dc.titleSuppression of high-fat diet-induced obesity-associated liver mitochondrial dysfunction by docosahexaenoic acid and hydroxytyrosol co-administration
dc.typeArticle


Este ítem pertenece a la siguiente institución